AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.51
-1.25 (-6.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.76
Open18.80
Bid17.33 x 1000
Ask17.55 x 1000
Day's Range17.49 - 19.37
52 Week Range2.35 - 23.34
Volume8,340,306
Avg. Volume8,286,136
Market Cap5.766B
Beta (3Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • GlobeNewswire16 hours ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KHC, AMRN, WTW and SYNH

    The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • PR Newswire19 hours ago

    Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

    NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller  announces investigation into possible securities laws violations in connection with allegations that Amarin administered ...

  • Stifel on Amarin (AMRN): Nothing Fishy About This Stock — It’s a Buy!
    SmarterAnalyst23 hours ago

    Stifel on Amarin (AMRN): Nothing Fishy About This Stock — It’s a Buy!

    Do you have high cholesterol? Investors in Amarin (AMRN) kind of hope that you do -- but ideally, not too high.Anywhere between 150 and 500 milligrams per deciliter of triglycerides will do just fine.Amarin, as you may be aware, is a commercial stage pharmaceutical company that focuses on treating hypertriglyceridemia (too many triglycerides in the bloodstream), which can lead to cardiovascular disease. Unlike many -- even most -- pharmaceutical companies that you may hear about, Amarin actually has a salable product, a purified omega-3 fatty acid derived from fish oil that it markets under the name "Vascepa."Marketed since 2012 for the treatment of triglyceride levels in excess of 500 mg/dL, Vascepa is well established in the market, and selling well enough to drive nearly $230 million in trailing revenues for Amarin last year (but no profits just yet, sorry).The good news is that that might change, and the reason it might change -- as Stifel analyst Derek Archila tells us in his initiation of coverage of Amarin stock with a "buy" rating and $27 price target. (To watch Archila's track record, click here)Archila believes the results of a clinical trial of Vascepa to treat high cholesterol in patients with triglyceride levels below 500 mg/dL, but above 150 mg/dL (levels considered anywhere from "borderline" to "high," but not quite "very high") have been "impressive." As Archila relates, this trial, known as the REDUCE-IT trial, revealed better than 25% reductions in the risk of cardiovascular disease for patients with borderline-to-high levels of triglycerides in their bloodstreams.Seeing these results, Archila notes that 95% of the physicians it surveyed, who already prescribe Vascepa, plan to prescribe Vascepa more often over the next 12 months, for borderline-to-high risk patients. Indeed, before the year is out, these doctors expect to have between 10% and 25% of their high cholesterol patients taking the drug. Moreover, among doctors who do not yet prescribe the drug, roughly 80% surveyed say they will begin prescribing Vascepa after seeing the results of the REDUCE-IT study.Based on the results of this trial, and physician reaction, Archila is convinced that as doctors increasingly prescribe Vascepa to treat even borderline-to-high levels of high cholesterol, "this will most certainly lead to robust growth" for Amarin -- and "likely [growth even] above management's 2019 guidance."How much growth are we talking about, exactly?For all of 2019, Archila is projecting $374 million in sales -- better than 60% growth over last year's revenues, and ahead of even Amarin's projections of $350 million. In 2020, the analyst sees Vascepa sales growing a further 50% (to $566 million), before ultimately peaking at $2.5 billion in annual sales in 2029.In terms of profits, Archila believes Amarin will turn the corner and earn its first profit ($0.03 per share) in Q4 this year, then proceed to earn $0.34 per share in 2020.Granted, even $0.34 per share isn't a huge amount of profit to justify Amarin's current near-$19 stock price. (It actually works out to a forward P/E ratio of 55). But if Amarin continues growing its sales at 50% and better, maybe -- just maybe -- the high price is worth it.Archila is certainly not the first analyst with an optimistic outlook for the fish oil drug maker, as TipRanks analytics showcasing AMRN stock as a Strong Buy. With an average price target of $31.60, analysts are predicting an upside of nearly 65%. In total, the stock has received 6 'buy' ratings in the last three months. (See AMRN's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Will New Streaming Service Propel Apple (AAPL) Stock to New Heights? * Analyst Commends Cannabis Stock Aurora (ACB) for Peltz Pick * This Cannabis Stock Just Got a Huge Vote of Confidence * Apple's (AAPL) Streaming Video Buzz: Should You Buy the Hype?

  • ACCESSWIRE23 hours ago

    CLASS ACTION UPDATE for DPLO, AMRN and BPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • Business Wireyesterday

    AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

    Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (AMRN). The lawsuit seeks to recover damages for Amarin investors under federal securities laws. To speak privately with an attorney regarding this class action lawsuit, call (800) 808-5294 or click here.

  • GlobeNewswire2 days ago

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN

    Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ:  AMRN) and certain of its officers.   The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (“Amarin” or the “Company”) between September 24, 2018 and November 9, 2018 (the “Class Period”), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Amarin securities between September 24, 2018, and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.

  • ACCESSWIRE2 days ago

    IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 21, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (''Amarin'' ...

  • ACCESSWIRE2 days ago

    SHAREHOLDER ALERT: ZIV DPLO AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / March 21, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...

  • GlobeNewswire2 days ago

    APRIL 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amarin Corporation plc – AMRN

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Amarin Corporation plc (AMRN) from September 24, 2018 through November 9, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Amarin investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2019.

  • GlobeNewswire3 days ago

    Class Action AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC Update

    Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

  • GlobeNewswire3 days ago

    SHAREHOLDER ALERT: MHLD AMRN INGN USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, March 20, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE3 days ago

    Bronstein, Gewirtz & Grossman, LLC Class Action Update AKRX, AMRN & CAG

    NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • ACCESSWIRE4 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (''Amarin'' or the ''Company'') (AMRN) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (''Amarin'' or the ''Company'') between September 24, 2018 and November 9, 2018 (the ''Class Period''), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the ''Exchange Act''). If you are a shareholder who purchased Amarin securities between September 24, 2018 and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.

  • GlobeNewswire4 days ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, SVXY, AMRN and NIO

    NEW YORK, March 19, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • GlobeNewswire4 days ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

    Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Amarin stock or options between September 24, 2018 and November 9, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMRN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

  • GlobeNewswire4 days ago

    CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, March 19, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • ACCESSWIRE4 days ago

    Class Action Update AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
    CNW Group4 days ago

    HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

    TORONTO , March 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (HLS.TO), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Amarin Corporation plc (AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT. HLS has in-licensed the exclusive rights to Vascepa for the Canadian market.

  • CNW Group4 days ago

    HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease

    HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease

  • GlobeNewswire4 days ago

    Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its previously announced data from scientific presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session from March 16-18, 2019 in New Orleans, LA, announced data from three presented scientific posters. Poster data also delved into potential mechanisms of action for Vascepa® (icosapent ethyl) capsules. In a poster titled, “Triglycerides as a Risk Factor for Coronary Heart Disease: What Measure and What Cutoff?”, research focused on triglyceride levels of people who had their first cardiovascular event.

  • GlobeNewswire5 days ago

    Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels

    BEDMINSTER, N.J. and DUBLIN, Ireland, March 18, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced.

  • Benzinga5 days ago

    Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study

    Amarin Corporation (NASDAQ: AMRN) presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study. Vascepa demonstrated a statistically significant 30 percent risk reduction in cardiovascular events compared to placebo in the statin-treated population in REDUCE-IT. Total events tracked in the study included a patient’s first and subsequent MACE occurrences.

  • Reuters5 days ago

    Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

    A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday. Compared with a placebo, Vascepa cut the combined rate of heart attacks, strokes, heart-related death, need for artery-clearing procedures and hospitalizations for unstable angina by 30 percent in heart disease patients at high risk for such events. Amarin in September released initial results from the study of 8,179 patients already taking other heart drugs that showed a 25 percent reduction of serious heart events for those receiving a 4 gram dose of Vascepa compared with placebo, data that sent its share price surging from around $3 to over $12.

  • Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
    PR Newswire5 days ago

    Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

    BEDMINSTER, N.J. and DUBLIN, March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT.

  • GlobeNewswire6 days ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP

    The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.